Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.04
NAS:OMER's Cash-to-Debt is ranked lower than
91% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:OMER: 1.04 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OMER' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.08 Max: 23.84
Current: 1.04
0.21
23.84
Equity-to-Asset 0.07
NAS:OMER's Equity-to-Asset is ranked lower than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:OMER: 0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OMER' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.24  Med: -0.31 Max: 0.7
Current: 0.07
-15.24
0.7
Debt-to-Equity 9.03
NAS:OMER's Debt-to-Equity is ranked lower than
99.99% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:OMER: 9.03 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:OMER' s Debt-to-Equity Range Over the Past 10 Years
Min: -18.36  Med: -0.83 Max: 9.03
Current: 9.03
-18.36
9.03
Debt-to-EBITDA -1.83
NAS:OMER's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:OMER: -1.83 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:OMER' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.83  Med: -0.59 Max: -0.04
Current: -1.83
-1.83
-0.04
Piotroski F-Score: 6
Altman Z-Score: -1.32
Beneish M-Score: -2.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -65.08
NAS:OMER's Operating Margin % is ranked higher than
52% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:OMER: -65.08 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OMER' s Operating Margin % Range Over the Past 10 Years
Min: -12988.5  Med: -1349.45 Max: -65.08
Current: -65.08
-12988.5
-65.08
Net Margin % -88.42
NAS:OMER's Net Margin % is ranked lower than
51% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:OMER: -88.42 )
Ranked among companies with meaningful Net Margin % only.
NAS:OMER' s Net Margin % Range Over the Past 10 Years
Min: -13668.46  Med: -1295.19 Max: -88.42
Current: -88.42
-13668.46
-88.42
ROA % -73.59
NAS:OMER's ROA % is ranked lower than
86% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:OMER: -73.59 )
Ranked among companies with meaningful ROA % only.
NAS:OMER' s ROA % Range Over the Past 10 Years
Min: -538.37  Med: -106.19 Max: -50.37
Current: -73.59
-538.37
-50.37
ROC (Joel Greenblatt) % -1580.90
NAS:OMER's ROC (Joel Greenblatt) % is ranked lower than
78% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:OMER: -1580.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OMER' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8254.24  Med: -3348.17 Max: -1580.9
Current: -1580.9
-8254.24
-1580.9
3-Year Revenue Growth Rate 163.90
NAS:OMER's 3-Year Revenue Growth Rate is ranked higher than
97% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:OMER: 163.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:OMER' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -17 Max: 163.9
Current: 163.9
0
163.9
3-Year EBITDA Growth Rate 3.70
NAS:OMER's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:OMER: 3.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:OMER' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.7 Max: 21.2
Current: 3.7
0
21.2
3-Year EPS without NRI Growth Rate 5.90
NAS:OMER's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:OMER: 5.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:OMER' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.5 Max: 19.8
Current: 5.9
0
19.8
GuruFocus has detected 2 Warning Signs with Omeros Corp NAS:OMER.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OMER's 30-Y Financials

Financials (Next Earnings Date: 2018-03-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

OMER Guru Trades in

OMER Guru Trades in

Q2 2016

OMER Guru Trades in Q2 2016

Joel Greenblatt Sold Out
» More
Q3 2017

OMER Guru Trades in Q3 2017

Paul Tudor Jones 16,271 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BOLD, XSWX:HBMN, NAS:ATNX, SAU:2070, NAS:CRSP, XMCE:ROVI, NYSE:BHVN, SZSE:002872, SZSE:300147, SZSE:300149, NAS:WVE, SZSE:300255, XPAR:ALCLS, XPAR:STAGR, XTER:BIO3, SZSE:300204, XKRX:003000, NAS:EPZM, XPAR:GNFT, NAS:ACOR » details
Traded in other countries:3O8.Germany,
Headquarter Location:USA
Omeros Corp is a biopharmaceutical company. It focuses on research and development of small-molecule and protein therapeutics to treat inflammation, coagulopathies, and disorders of the central nervous system and sells Omidria for cataract surgeries.

Omeros Corp is a U.S.-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Top Ranked Articles about Omeros Corp

New Research Coverage Highlights Wells Fargo, Omeros, Uranium Energy, Advisory Board, Twenty-First Century Fox, and SiteOne Landscape Supply — Consolidated Revenues, Company Growth, and Expectations for 2018
Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Why Markets Might Have Got It Wrong With Omeros My take on the shorting situation
Omeros Corp. (NASDAQ:OMER) has spent the majority of the last few months as the subject of intense debate in the biotechnology space. The company, which is working to develop a variety of drugs targeting rare diseases, fell foul of a report published in June by a research group that goes by the pseudonym Art Doyle. The report attacked Omeros' lead development program, which is investigating the safety and efficacy of a drug called OMS721 in a target indication of atypical hemolytic uremic syndrome (aHUS), highlighting several so-called deficiencies associated with the current publicly available information to the program. Read more...
Covered Call reports for Akamai Technologies, Cheesecake Factory, NVIDIA, Omeros and Tesla Motors include trade ideas that offer returns of up to 55%

Ratios

vs
industry
vs
history
PB Ratio 90.83
OMER's PB Ratio is ranked lower than
99.99% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OMER: 90.83 )
Ranked among companies with meaningful PB Ratio only.
OMER' s PB Ratio Range Over the Past 10 Years
Min: 2.77  Med: 9.15 Max: 111.88
Current: 90.83
2.77
111.88
PS Ratio 12.15
OMER's PS Ratio is ranked lower than
59% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. OMER: 12.15 )
Ranked among companies with meaningful PS Ratio only.
OMER' s PS Ratio Range Over the Past 10 Years
Min: 8.16  Med: 31.84 Max: 1667.33
Current: 12.15
8.16
1667.33
EV-to-EBIT -18.16
OMER's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. OMER: -18.16 )
Ranked among companies with meaningful EV-to-EBIT only.
OMER' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.3  Med: -6.9 Max: -2.1
Current: -18.16
-22.3
-2.1
EV-to-EBITDA -18.33
OMER's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. OMER: -18.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMER' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.5  Med: -6.9 Max: -2.2
Current: -18.33
-22.5
-2.2
EV-to-Revenue 13.02
OMER's EV-to-Revenue is ranked lower than
59% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. OMER: 13.02 )
Ranked among companies with meaningful EV-to-Revenue only.
OMER' s EV-to-Revenue Range Over the Past 10 Years
Min: 9.2  Med: 41.4 Max: 1629.7
Current: 13.02
9.2
1629.7
Current Ratio 4.78
OMER's Current Ratio is ranked lower than
72% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OMER: 4.78 )
Ranked among companies with meaningful Current Ratio only.
OMER' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 2.22 Max: 6.61
Current: 4.78
0.41
6.61
Quick Ratio 4.74
OMER's Quick Ratio is ranked lower than
69% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. OMER: 4.74 )
Ranked among companies with meaningful Quick Ratio only.
OMER' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 2.2 Max: 6.61
Current: 4.74
0.41
6.61
Days Inventory 383.47
OMER's Days Inventory is ranked lower than
89% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. OMER: 383.47 )
Ranked among companies with meaningful Days Inventory only.
OMER' s Days Inventory Range Over the Past 10 Years
Min: 182.32  Med: 194.56 Max: 383.47
Current: 383.47
182.32
383.47
Days Sales Outstanding 140.20
OMER's Days Sales Outstanding is ranked lower than
82% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. OMER: 140.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMER' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.06  Med: 95.58 Max: 265.45
Current: 140.2
36.06
265.45
Days Payable 1.00
OMER's Days Payable is ranked higher than
97% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. OMER: 1.00 )
Ranked among companies with meaningful Days Payable only.
OMER' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 1452.49 Max: 2253.81
Current: 1
1
2253.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.00
OMER's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. OMER: -13.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMER' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -98.1  Med: -13 Max: 0
Current: -13
-98.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 581.33
OMER's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. OMER: 581.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OMER' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.58  Med: 12.56 Max: 701.67
Current: 581.33
3.58
701.67
Price-to-Tangible-Book 91.79
OMER's Price-to-Tangible-Book is ranked lower than
99.99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. OMER: 91.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OMER' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.46  Med: 10.61 Max: 109.64
Current: 91.79
3.46
109.64
Price-to-Median-PS-Value 0.38
OMER's Price-to-Median-PS-Value is ranked higher than
80% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OMER: 0.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMER' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.16 Max: 51.63
Current: 0.38
0.3
51.63
Earnings Yield (Greenblatt) % -5.51
OMER's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. OMER: -5.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMER' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -46.6  Med: -14.5 Max: -4.5
Current: -5.51
-46.6
-4.5

More Statistics

Revenue (TTM) (Mil) $63.97
EPS (TTM) $ -1.29
Beta3.61
Short Percentage of Float19.26%
52-Week Range $8.71 - 27.09
Shares Outstanding (Mil)21.29

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 70 87 133 170
EPS ($) -1.06 -0.66 0.49 1.16
EPS without NRI ($) -1.06 -0.66 0.49 1.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}